The DOI matches its Crossref record; 86 of the 86 references it cites were found in a registry or an index.
Design and Validation of Liposomal ApoE2 Gene Delivery System to Evade Blood–Brain Barrier for Effective Treatment of Alzheimer’s Disease
Open accessAbstract
Targeting gene-based therapeutics to the brain is a strategy actively sought to treat Alzheimer’s disease (AD). Recent findings discovered the role of apolipoprotein E (ApoE) isoforms in the clearance of toxic amyloid beta proteins from the brain. ApoE2 isoform is beneficial for preventing AD development, whereas ApoE4 is a major contributing factor to the disease. In this paper, we demonstrated efficient brain-targeted delivery of ApoE2 encoding plasmid DNA (pApoE2) using glucose transporter-1 (glut-1) targeted liposomes. Liposomes were surface-functionalized with a glut-1 targeting ligand mannose (MAN) and a cell-penetrating peptide (CPP) to enhance brain-targeting and cellular internalization, respectively. Among various CPPs, rabies virus glycoprotein peptide (RVG) or penetratin (Pen) was selected as a cell-penetration enhancer. Dual (RVGMAN and PenMAN)-functionalized liposomes were cytocompatible at 100 nM phospholipid concentration and demonstrated significantly higher expression of ApoE2 in bEnd.3 cells, primary neurons, and astrocytes compared to monofunctionalized and unmodified (plain) liposomes. Dual-modified liposomes also showed ∼2 times higher protein expression than other formulation controls in neurons cultured below the in vitro BBB model. These results translated well to in vivo efficacy study with significantly higher transfection of pApoE2 in the C57BL/6 mice brain following single tail vein administration of RVGMAN and PenMAN functionalized liposomes without any noticeable signs of toxicity. These results illustrate the potential of surface-modified liposomes for safe and brain-targeted delivery of the pApoE2 gene for effective AD therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“However, while ApoE2 is beneficial for preventing AD development, ApoE4 is a contributing factor to AD progression [101].”
From Advances in Strategies to Transport Nanoparticles Across the Blood–Brain Barrier for Drug Delivery into the Brain for the Treatment of Alzheimer’s Disease (2026) · cites this paper as [101]
The cited source says what the claim attributes to it.
In the citing paper
“The results showed that dual-modified liposomes resulted in ∼2 times higher ApoE2 protein expression in the brain of mice compared to endogenous ApoE levels.”
From Advances in Strategies to Transport Nanoparticles Across the Blood–Brain Barrier for Drug Delivery into the Brain for the Treatment of Alzheimer’s Disease (2026) · cites this paper as [101]
The cited source says what the claim attributes to it.
In the citing paper
“Plain or monofunctionalized liposomes resulted in ∼1.25 times higher expression than the endogenous one.”
From Advances in Strategies to Transport Nanoparticles Across the Blood–Brain Barrier for Drug Delivery into the Brain for the Treatment of Alzheimer’s Disease (2026) · cites this paper as [101]
The cited source says what the claim attributes to it.
In the citing paper
“Arora et al. [101] demonstrated efficient brain-targeted delivery of pApoE2 using GLUT-1-targeted, dual-functionalized liposomes, in in vitro (Transwell BBB model) and in vivo (C57BL/6 mice) studies.”
From Advances in Strategies to Transport Nanoparticles Across the Blood–Brain Barrier for Drug Delivery into the Brain for the Treatment of Alzheimer’s Disease (2026) · cites this paper as [101]
The cited source says what the claim attributes to it.
In the citing paper
“Results in vitro showed that dual-functionalized liposomes had 2 times greater transfection efficiency than plain and monofunctionalized liposomes.”
From Advances in Strategies to Transport Nanoparticles Across the Blood–Brain Barrier for Drug Delivery into the Brain for the Treatment of Alzheimer’s Disease (2026) · cites this paper as [101]
The cited source says what the claim attributes to it.
In the citing paper
“Following single-tail vein administration, the use of these liposomes to encapsulate the ApoE2/chitosan complex proved to significantly enhance the transport and transfection of the ApoE2 gene across the BBB in in vivo models, without any noticeable signs of toxicity.”
From Advances in Strategies to Transport Nanoparticles Across the Blood–Brain Barrier for Drug Delivery into the Brain for the Treatment of Alzheimer’s Disease (2026) · cites this paper as [101]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Danaei, M., Dehghankhold, M., Ataei, S., Davarani, F. H., Javanmard, R., Dokhani, A., Khorasani, S., & Mozafari, M. R. (2018) · Pharmaceutics · doi:10.3390/pharmaceutics10020057 · Cited by 4,967
PEGylation as a strategy for improving nanoparticle-based drug and gene delivery
Suk, J. S., Xu, Q., Kim, N., Hanes, J., & Ensign, L. M. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.09.012 · Cited by 4,523
Association of apolipoprotein E allele ϵ4 with late‐onset familial and sporadic Alzheimer's disease
Saunders, A. M., Strittmatter, W. J., Schmechel, D., St. George-Hyslop, P. H., Pericak-Vance, M. A., Joo, S. H., Rosi, B. L., Gusella, J. F., Crapper-MacLachlan, D. R., Alberts, M. J., et al. (1993) · Neurology · doi:10.1212/wnl.43.8.1467 · Cited by 3,786
Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy
Liu, C.-C., Kanekiyo, T., Xu, H., & Bu, G. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.263 · Cited by 3,459
The role of surface charge in cellular uptake and cytotoxicity of medical nanoparticles
Fröhlich, E. (2012) · International Journal of Nanomedicine · doi:10.2147/ijn.s36111 · Cited by 2,561
Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes
Klibanov, A. L., Maruyama, K., Torchilin, V. P., & Huang, L. (1990) · FEBS Letters · doi:10.1016/0014-5793(90)81016-h · Cited by 2,030
2018 Alzheimer's disease facts and figures
Alzheimer's Association (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.001 · Cited by 1,912
Alzheimer Mechanisms and Therapeutic Strategies
Huang, Y., & Mucke, L. (2012) · Cell · doi:10.1016/j.cell.2012.02.040 · Cited by 1,758
Alzheimer’s disease drug-development pipeline: Few candidates, frequent failures
Cummings, J. L., Morstorf, T., & Zhong, K. (2014) · Alzheimer's Research & Therapy · doi:10.1186/alzrt269 · Cited by 1,744
Astrocytes induce blood–brain barrier properties in endothelial cells
Janzer, R. C., & RAFF, M. C. (1987) · Nature · doi:10.1038/325253a0 · Cited by 1,613
Research works printed but not linked: 1
- Gardlík R., 2005, Med. Sci. Monit., 11, RA110
Cited by
Sorted by citations
Items 101–149 of 149
Targeting angiogenesis, inflammation, and oxidative stress in Alzheimer's diseases
Bhandari, M., Tiwari, R. K., Chanda, S., & Bonde, G. V. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13587-3.00003-5 · Cited by 3
Silva, R., Monteiro, J., Ramalho, M. J., Andrade, S., Loureiro, J. A., & Pereira, M. C. (2026) · Pharmaceuticals · doi:10.3390/ph19050685 · Cited by 2
“Arora et al. [101] demonstrated efficient brain-targeted delivery of pApoE2 using GLUT-1-targeted, dual-functionalized liposomes, in in vitro (Transwell BBB model) and in vivo (C57BL/6 mice) studies.”
InfluentialSurface engineered nano architectonics: An evolving paradigm for tackling Alzheimer's disease
Negi, M., Amulya, E., Phatale, V., Abraham, N., Hedaoo, A., Srinivasarao, D. A., & Srivastava, S. K. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.123155 · Cited by 2
Arciuolo, V., D’Aria, F., Caruso, M. R., Calvino, M. M., Amato, J., Lazzara, G., Milioto, S., Giancola, C., Cavallaro, G. P., & Pagano, B. (2025) · The Chemical Record · doi:10.1002/tcr.202500126 · Cited by 2
Chaudhary, S., Kumar, P., & Kaushik, M. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.142896 · Cited by 2
Micelles-based drug delivery for dementia
Katari, O., Yadav, S., Akhtar, J., & Jain, S. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-824331-2.00002-9 · Cited by 4
Liposome: A potential drug delivery vector to treat dementia
Agrawal, M., Roy, U., & Alexander, A. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-824331-2.00010-8 · Cited by 2
CPP Functionalized Nanoparticles
Langel, Ü. (2023) · Springer eBooks · doi:10.1007/978-3-031-38731-9_17 · Cited by 1
Nanomaterials and Neurological Disorders Management
Sahu, S., Gantayat, D., Sahu, S. K., Kaur, G., Dwibedi, V., & Rath, S. K. (2024) · Smart nanomaterials technology · doi:10.1007/978-981-97-0308-1_5 · Cited by 1
Lamptey, R. N. L., Sun, C., & Singh, J. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117790 · Cited by 2
Self-citationPeyvand, P., Allami, P., & Rezaei, N. (2025) · Reviews in the Neurosciences · doi:10.1515/revneuro-2025-0025 · Cited by 1
Muolokwu, C. E., Gothwal, A., Kanekiyo, T., & Singh, J. (2025) · Pharmaceutical Research · doi:10.1007/s11095-025-03900-9 · Cited by 1
Self-citationTyagi, S., Kumar, J., & Kumar, S. (2025) · Journal of Dispersion Science and Technology · doi:10.1080/01932691.2025.2580488 · Cited by 1
Vojdanitalab, K., Naderi, M., Kalkhajeh, S. G., Sabetghadam, A., & Pashaki, S. R. (2026) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2026.108200 · Cited by 3
Chaulagain, B., Gothwal, A., Mahanta, A. K., Jarajapu, Y. P. R., & Singh, J. (2026) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5c01009 · Cited by 1
Self-citationBeliraya, J., Seenivasan, R., Halagali, P., Rathnanand, M., & Tippavajhala, V. K. (2026) · AAPS PharmSciTech · doi:10.1208/s12249-026-03453-z · Cited by 2
Stein, J. B., Arif, M., Cheung, H., & Lee, K. (2026) · Cell Biomaterials · doi:10.1016/j.celbio.2026.100495 · Cited by 2
Emerging diagnostic biomarkers and therapeutic targets in Alzheimer's disease
Dineshbhai, T. K., Rafaliya, D., Singh, A., Maheshwari, S., Lalan, M. S., & Chakraborthy, G. S. (2026) · Inflammopharmacology · doi:10.1007/s10787-026-02341-z · Cited by 1
Current Perspectives of Nanotherapeutics for the Treatment of Alzheimer’s Disease
Mishra, S., Senthilkumar, D., & Yadav, V. K. (2024) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9789815256505124010010 · Cited by 1
Mude, L., Swain, S. S., Karri, V. V. S. R., Kuppusamy, G., & Subramaniyan, V. (2024) · Springer eBooks · doi:10.1007/978-981-96-0259-9_11 · Cited by 1
Nanoparticles – a novel theranostic approach to treat alzheimer’s disease
Bashir, W. Q., & Shahzadi, S. (2022) · Journal of Applied Biotechnology & Bioengineering · doi:10.15406/jabb.2022.09.00312 · Cited by 1
Eswaran, L., Kazimirsky, G., Yehuda, R., & Byk, G. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15030961 · Cited by 1
Treatment for alzheimer's disease: The present and future
Wei, C. (2021) · E3S Web of Conferences · doi:10.1051/e3sconf/202127103018
Liposomes: An Emerging Carrier for Brain Targetting and DeliveryPreprint
Pandian, S. R. K., Vijayakumar, K. K., Murugesan, S., & Kunjiappan, S. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3988692
Langel, Ü. (2023) · Springer eBooks · doi:10.1007/978-3-031-38731-9_9
Lamptey, R. N. L., Sun, C., & Singh, J. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102210
Self-citationGhosh, K., Afrose, N., Chakraborty, R., Hazra, A., Bhowmick, P., & Bhowmick, M. (2024) · Current Nanomedicine · doi:10.2174/0124681873327772240916071354
Nano Biomaterials for Neurological Theranostics
Muhammad, M., & Elsherbiny, S. M. (2024) · Advances in medical diagnosis, treatment, and care (AMDTC) book series · doi:10.4018/979-8-3693-3065-4.ch008
Upcoming Nano and Conventional Drug Delivery Strategies for Alzheimer’s Disease
Varghese, N. M., Sathyamoorthy, N., Krishnamurthy, P. T., Varshini, M. S., & Chintamaneni, P. K. (2024) · Springer eBooks · doi:10.1007/978-981-96-0259-9_16
Silva, A., Grosso, C., Barroso, M. F., Prieto, M. A., Delerue-Matos, C. M., & Soares, C. M. D. (2024) · Springer eBooks · doi:10.1007/978-981-97-7445-6_35
Nano lipid-drug conjugates for the treatment of Alzheimer’s disease
Mandal, S., & Das, M. K. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33382-8.00010-8
REVOLUTIONIZING ALZHEIMER’S THERAPEUTICS: FROM MICROTECHNOLOGIES TO AI-DRIVEN INNOVATIONS
Lahiri, A., Balamuralidhara, V., Manohar, S. K., & R., A. A. (2025) · International Journal of Applied Pharmaceutics · doi:10.22159/ijap.2025v17i3.53726
Proteins, peptides and its derivatives as ligand and applications in drug delivery
Triveni, T., Kaul, S., Nagaich, U., Mishra, D. K., Pandey, M., & Jain, N. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33366-8.00002-6
Jaitawat, D. P. S., Singh, I., & Chauhan, S. B. (2025) · Recent Advances in Drug Delivery and Formulation · doi:10.2174/0126673878361646250623062415
From Imaging to Drug Delivery and Treatment
Mousavi-Sagharchi, S. M. A., Ranjbar-Jamalabadi, M., Yavari, S., Afrazeh, E., Poondla, N., & Sheykhhasan, M. (2025) · IGI Global eBooks · doi:10.4018/979-8-3373-0055-9.ch004
Grzeczkowicz, A., Kwiatkowska, A., Lipko, A., Kazimierczak, B., & Granicka, L. H. (2025) · Membranes · doi:10.3390/membranes15100313
Liposomes: formulation, functionalization, properties, and their biomedical applications
Elaı̈ssari, A., & Khizar, S. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-27406-0.00008-3
Application of CRISPR/Cas9 Gene Editing Technology in Targeted Therapy of Alzheimer's Disease
Fan, Y. (2025) · Highlights in Science Engineering and Technology · doi:10.54097/x8m0p842
Llorente, X., Esteruelas, G., García, M. B. G., Souto, E. B., & Sánchez-López, E. (. (2026) · Advances in pharmacology · doi:10.1016/bs.apha.2026.03.002
Saraswat, A., Nomani, A., Rayaprolu, B. M., Bhalla, A. S., & Shameem, M. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-36453-2.00004-5
Nagdev, S., Tantray, J., Haswani, N. G., Zawar, L., Patel, S., & Prajapati, B. (2026) · Nano Trends · doi:10.1016/j.nwnano.2026.100214
Gothwal, A., Muolokwu, C. E., Belin, M. A. F., Tagoe, B., Frey, W. H., Zhao, J., Parsons, T. M., Kanekiyo, T., & Singh, J. (2026) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2026.152803
Self-citationYusuf, A., Harati, R., Greish, K., & Haider, M. A. (2026) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2026.108594
Apolipoprotein E in drug delivery systems—targeted pharmacotherapeutics
Pandey, J., & Jain, S. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-40563-1.00009-0
Curcumin-Based Nanocarriers for Alzheimer’s Disease: A Promising Therapeutic Avenue
Jayalath, W. T., Gunaratna, M. J., Kadigamuwa, C. C., Thambiliyagodage, C. J., & Dahanayake, J. N. (2026) · Applied Biosciences · doi:10.3390/applbiosci5030069
Nucleic acid drug therapies for CNS diseases: Present status and future perspectives
Chen, Y., Kuriakose, D., & Xiao, Z. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-44631-3.00006-8
Zheng, Y., Fang, Z., & Chen, Z. (2026) · Targetome · doi:10.48130/targetome-0026-0044
Bridging the translational gap in clinical nanomedicine: From rational design to clinical reality
Ghonaim, A. H., El-Naka, M. A., Nageeb, W. M., Khan, A. U., Seleem, N. M., Abdelghafar, A., Zamel, D., Liu, Y., He, Q., & Li, W. (2026) · BMEMat · doi:10.1002/bmm2.70133
Wenhua, Y., Wenjing, M., Yan, D., Fei, L., Chen, J., Xia, T., Guan, Y., Xin, L., Huang, Y., Guo, Y., et al. (2026) · Frontiers in Neurology · doi:10.3389/fneur.2026.1934307
Metadata
- Authors
- Arora, S., Layek, B., & Singh, J.
- Affiliations
- North Dakota State University (US)
- Corresponding author
- Singh, Jagdish
- Venue
- Molecular Pharmaceutics
- Publisher
- American Chemical Society (ACS)
- Published
- 2020-08-11
- Volume
- 18
- Issue
- 2
- Pages
- 714-725
- ISSN
- 1543-8384 (ISSN-L)
- 1543-8392
- PMC
- PMC10292003
- OpenAlex
- W3048402510
- Cited by
- 149
- References
- 86
- Citations by year
- 2026: 18 · 2025: 31 · 2024: 36 · 2023: 25 · 2022: 25 · 2021: 14
- FWCI
- 5.19
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- Locations
- Molecular Pharmaceutics (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute on Aging (R01AG051574)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Keywords
- Alzheimer's disease, apolipoprotein E2, gene delivery, liposomes, blood-brain barrier, glucose transporter 1, cell-penetrating peptides, penetratin, plasmid transfection, brain-targeted delivery, amyloid-beta clearance, bEnd.3 cells, astrocytes, in vitro BBB model, in vivo transfection
- MeSH terms
- Alzheimer Disease, Animals, Astrocytes, Blood-Brain Barrier, Brain, Cell Line, Drug Compounding, Female, Humans, Liposomes, Male, Neurons, Gene Transfer Techniques, Models, Animal, Glucose Transporter Type 1, Mice, Rats, Apolipoprotein E2, Cell-Penetrating Peptides, Primary Cell Culture
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
